» Articles » PMID: 17592646

Repression of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) but Not Its Receptors During Oral Cancer Progression

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2007 Jun 27
PMID 17592646
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: TRAIL plays an important role in host immunosurveillance against tumor progression, as it induces apoptosis of tumor cells but not normal cells, and thus has great therapeutic potential for cancer treatment. TRAIL binds to two cell-death-inducing (DR4 and DR5) and two decoy (DcR1, and DcR2) receptors. Here, we compare the expression levels of TRAIL and its receptors in normal oral mucosa (NOM), oral premalignancies (OPM), and primary and metastatic oral squamous cell carcinomas (OSCC) in order to characterize the changes in their expression patterns during OSCC initiation and progression.

Methods: DNA microarray, immunoblotting and immunohistochemical analyses were used to examine the expression levels of TRAIL and its receptors in oral epithelial cell lines and in archival tissues of NOM, OPM, primary and metastatic OSCC. Apoptotic rates of tumor cells and tumor-infiltrating lymphocytes (TIL) in OSCC specimens were determined by cleaved caspase 3 immunohistochemistry.

Results: Normal oral epithelia constitutively expressed TRAIL, but expression was progressively lost in OPM and OSCC. Reduction in DcR2 expression levels was noted frequently in OPM and OSCC compared to respective patient-matched uninvolved oral mucosa. OSCC frequently expressed DR4, DR5 and DcR1 but less frequently DcR2. Expression levels of DR4, DR5 and DcR1 receptors were not significantly altered in OPM, primary OSCC and metastatic OSCC compared to patient-matched normal oral mucosa. Expression of proapoptotic TRAIL-receptors DR4 and DR5 in OSCC seemed to depend, at least in part, on whether or not these receptors were expressed in their parental oral epithelia. High DR5 expression in primary OSCC correlated significantly with larger tumor size. There was no significant association between TRAIL-R expression and OSSC histology grade, nodal status or apoptosis rates of tumor cells and TIL.

Conclusion: Loss of TRAIL expression is an early event during oral carcinogenesis and may be involved in dysregulation of apoptosis and contribute to the molecular carcinogenesis of OSCC. Differential expressions of TRAIL receptors in OSCC do not appear to play a crucial role in their apoptotic rate or metastatic progression.

Citing Articles

Podoplanin immunoexpression in odontogenic lesions: a systematic review, meta-analysis, and integrated bioinformatic analysis.

Alarcon-Sanchez M, Luna-Bonilla G, Romero-Servin S, Heboyan A Diagn Pathol. 2024; 19(1):115.

PMID: 39182093 PMC: 11344317. DOI: 10.1186/s13000-024-01540-y.


Research progress in the establishment of pancreatic cancer models and preclinical applications.

Wu W, Wen K, Zhong Y Cancer Innov. 2023; 1(3):207-219.

PMID: 38089760 PMC: 10686130. DOI: 10.1002/cai2.31.


Emerging Role of Decoy Receptor-2 as a Cancer Risk Predictor in Oral Potentially Malignant Disorders.

de Villalain L, Alvarez-Teijeiro S, Rodriguez-Santamarta T, Fernandez Del Valle A, Allonca E, Rodrigo J Int J Mol Sci. 2023; 24(18).

PMID: 37762685 PMC: 10531848. DOI: 10.3390/ijms241814382.


TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma.

DallOra M, Rovesti G, Reggiani Bonetti L, Casari G, Banchelli F, Fabbiani L Am J Cancer Res. 2021; 11(9):4500-4514.

PMID: 34659901 PMC: 8493377.


Apoptosis and genes involved in oral cancer - a comprehensive review.

Dwivedi R, Pandey R, Chandra S, Mehrotra D Oncol Rev. 2020; 14(2):472.

PMID: 32685111 PMC: 7365992. DOI: 10.4081/oncol.2020.472.


References
1.
McCarthy M, Sznol M, DiVito K, Camp R, Rimm D, Kluger H . Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res. 2005; 11(14):5188-94. DOI: 10.1158/1078-0432.CCR-05-0158. View

2.
Teng M, Brandwein-Gensler M, Teixeira M, Martignetti J, Duffey D . A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2005; 131(5):407-12. DOI: 10.1001/archotol.131.5.407. View

3.
Nagaraj N, Vigneswaran N, Zacharias W . Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells. J Cancer Res Clin Oncol. 2005; 132(3):171-83. PMC: 5774671. DOI: 10.1007/s00432-005-0053-9. View

4.
Vigneswaran N, Beckers S, Waigel S, Mensah J, Wu J, Mo J . Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp Mol Pathol. 2005; 80(2):147-59. DOI: 10.1016/j.yexmp.2005.09.011. View

5.
Frey A, Monu N . Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J Leukoc Biol. 2006; 79(4):652-62. DOI: 10.1189/jlb.1105628. View